BCM
ETTX

BlueCrest Capital Management’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History

BlueCrest Capital Management’s Portfolio ETTX Stock Details ETTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-17,442
Closed -$190K – 1573
2018
Q3 		$190K Buy
+17,442
New +$183K 0.01% 1290

Other funds holding ETTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlueCrest Capital Management's ETTX Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q4 2018, closing a stake of 17,442 shares — an estimated $190K sold.

BlueCrest Capital Management first reported a position in ETTX in Q3 2018 and held it in 1 quarter. The position peaked at $190K in Q3 2018. 20 funds tracked by Wall St. Rank hold ETTX as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Entasis Therapeutics Holdings Inc. position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 17,442 Entasis Therapeutics Holdings Inc. shares in Q4 2018, an estimated $190K.
  • BlueCrest Capital Management first reported a position in Entasis Therapeutics Holdings Inc. in Q3 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Entasis Therapeutics Holdings Inc. position peaked at $190K in Q3 2018.
  • 20 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.